Skip to main content

Table 2 Characteristics of patients suspected of pertussis in Perú during 2012

From: Increase in pertussis cases along with high prevalence of two emerging genotypes of Bordetella pertussis in Perú, 2012

 

PCR-negative n = 649 (%)

PCR-positive n = 191 (%)

P value

Gender

 Male

300 (46.2)

90 (47.1)

0.827

 Female

349 (53.8)

101 (52.9)

 

Vaccine

 Yes

265 (40.8)

82 (42.9)

0.81

 No

182 (28.0)

59 (30.9)

 

 No data

202 (31.1)

50 (26.2)

 

Vaccine dosesa

 0–3 doses

331 (74.0)

133 (94.3)

<0.00001*

 4–5 doses

116 (26.0)

8 (5.7)

 

Clinical symptoms

   

 Persistent cough

460 (70.9)

160 (83.8)

0.00037*

 Paroxysmal cough

416 (64.1)

147 (77.0)

0.00089*

 Vomiting after coughing

97 (14.9)

114 (59.7)

<0.00001*

 Stridor

177 (27.3)

71 (37.2)

0.0084*

 Apnea

147 (22.7)

59 (30.9)

0.02

Cough (days)

 1–6

132 (20.3)

43 (22.5)

0.51

 7–12

93 (14.3)

46 (24.1)

0.0014*

 13–15

70 (10.8)

39 (20.4)

0.0005*

  > 20

68 (10.5)

12 (6.3)

0.082

 No cough

286 (44.1)

51 (26.7)

 

Hospitalization

 Yes

113 (17.4)

67 (35.1)

<0.00001*

 No

363 (55.9)

81 (42.4)

 

 Not indicated

173 (26.7)

43 (22.5)

 

Antibiotica

 Yes

197 (41.0)

100 (52.4)

 Azithromycin

29 (14.7)

30 (30.0)

 Erythromycin

56 (28.4)

25 (25.0)

 Penicillins

54 (27.4)

22 (22.0)

 Others

58 (29.4)

23 (23.0)

Antibiotic (days of treatment)a

  

 1–3d

71 (10.9)

31 (16.2)

 4–6d

28 (4.3)

16 (8.4)

  ≥ 7d

17 (2.6)

14 (7.3)

 Not indicated

81 (12.5)

39 (20.4)

Etiology

  

B. pertussis

0 (0)

145 (75.9)

B. parapertussis

0 (0)

2 (1.0)

Bordetella sp.

0 (0)

44 (23.0)

  1. *Chi-square (X 2) test (p <0.05)
  2. aPercentages were calculated only in the population known to have been vaccinated or only in the recipients of an antibiotic
  3. Of the total of 840 pertussis-suspected cases reported in 2012 in Perú, only 3 were treated with Cotrimoxazol